ATE437949T1 - Gpr8 ligand und dafuer kodierende dna - Google Patents

Gpr8 ligand und dafuer kodierende dna

Info

Publication number
ATE437949T1
ATE437949T1 AT01941117T AT01941117T ATE437949T1 AT E437949 T1 ATE437949 T1 AT E437949T1 AT 01941117 T AT01941117 T AT 01941117T AT 01941117 T AT01941117 T AT 01941117T AT E437949 T1 ATE437949 T1 AT E437949T1
Authority
AT
Austria
Prior art keywords
gpr8
ligand
dna coding
dna
gpr8 ligand
Prior art date
Application number
AT01941117T
Other languages
English (en)
Inventor
Masaaki Mori
Yukio Shimomura
Mioko Harada
Mika Goto
Chieko Kitada
Taiji Asami
Yoshio Matsumoto
Yuka Adachi
Takuya Watanabe
Tsukasa Sugo
Michiko Abe
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE437949T1 publication Critical patent/ATE437949T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01941117T 2000-06-21 2001-06-20 Gpr8 ligand und dafuer kodierende dna ATE437949T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000191089 2000-06-21
JP2000275013 2000-09-06
JP2001116000 2001-04-13
PCT/JP2001/005257 WO2001098494A1 (fr) 2000-06-21 2001-06-20 Ligand de gpr8 et son adn

Publications (1)

Publication Number Publication Date
ATE437949T1 true ATE437949T1 (de) 2009-08-15

Family

ID=27343845

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01941117T ATE437949T1 (de) 2000-06-21 2001-06-20 Gpr8 ligand und dafuer kodierende dna

Country Status (7)

Country Link
US (2) US7193033B2 (de)
EP (1) EP1293567B1 (de)
AT (1) ATE437949T1 (de)
AU (1) AU2001274562A1 (de)
CA (1) CA2413195C (de)
DE (1) DE60139399D1 (de)
WO (1) WO2001098494A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247440B2 (en) 2001-05-15 2007-07-24 Takeda Pharmaceutical Company Limited Method of screening preventives or remedies for obesity
WO2002102847A1 (fr) * 2001-06-14 2002-12-27 Takeda Chemical Industries, Ltd. Nouveau ligand et son adn
WO2003057236A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Inhibiteur de prise de poids corporel
WO2003081234A2 (en) * 2002-03-26 2003-10-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with homo sapiens g - protein - coupled receptor 8 (gpr8)
AU2003221533A1 (en) * 2002-03-29 2003-10-13 Euroscreen Sa Ligands for g protein coupled receptor gpr7 and uses thereof
AU2003277553A1 (en) * 2002-11-06 2004-06-07 Takeda Pharmaceutical Company Limited Antidiuretics
US20070042947A1 (en) * 2003-03-13 2007-02-22 Takeda Pharmaceutical Company Limited Agents for preventing and/or treating uppper digestive tract disorders
US7763716B2 (en) 2003-05-28 2010-07-27 Takeda Pharmaceutical Company Limited Antibody against NPW
JP4504098B2 (ja) * 2003-05-28 2010-07-14 武田薬品工業株式会社 抗体およびその用途
CN101631454A (zh) 2006-12-08 2010-01-20 衣阿华州立大学研究基金公司 参与硝酸盐吸收和代谢的植物基因
KR20100069651A (ko) * 2007-09-11 2010-06-24 몬도바이오테크 래보래토리즈 아게 Ｈｃｍｖ 감염의 치료를 위한 치료제로서의 ｂｕｂｕｃ 및 임의의 ｅａａ－ｍａｒｔ１（２６－３５）의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5591602A (en) * 1993-11-05 1997-01-07 O'dowd; Brian F. Nucleic acid encoding opioid receptor
JPH09121865A (ja) * 1995-10-30 1997-05-13 Takeda Chem Ind Ltd 新規ｇ蛋白質共役型レセプター蛋白質、その製造法および用途
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
WO2002008417A1 (fr) * 2000-07-25 2002-01-31 Takeda Chemical Industries, Ltd. Procede de production d'une proteine de recombinaison
AU2002218495A1 (en) * 2000-11-30 2002-06-11 Takeda Chemical Industries Ltd. Novel g protein-coupled receptor proteins and dnas thereof
US7247440B2 (en) * 2001-05-15 2007-07-24 Takeda Pharmaceutical Company Limited Method of screening preventives or remedies for obesity

Also Published As

Publication number Publication date
EP1293567B1 (de) 2009-07-29
DE60139399D1 (de) 2009-09-10
CA2413195C (en) 2012-01-17
US7671174B2 (en) 2010-03-02
WO2001098494A1 (fr) 2001-12-27
US7193033B2 (en) 2007-03-20
EP1293567A4 (de) 2005-02-16
CA2413195A1 (en) 2002-12-17
US20050153391A1 (en) 2005-07-14
EP1293567A1 (de) 2003-03-19
AU2001274562A1 (en) 2002-01-02
US20080305998A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
ATE437949T1 (de) Gpr8 ligand und dafuer kodierende dna
EP1638950A4 (de) Cyclohexylglycinderivate als dipeptidylpeptidaseinhibitoren zur behandlung bzw. prevention von diabetes
NO20035488D0 (no) HV-protease-inhibitorer, blandinger inneholdende disse, deres farmas degree ytiskeanvendelser og materialer for deres syntese
IS6785A (is) EP4 viðtakahindrar til meðhöndlunar á liðagigt
ATE337191T1 (de) Doppelbrechende markierung
DE69022150D1 (de) Neue Peptidasen und Isomerasen-Inhibitoren.
DK1576112T3 (da) Cytokin-receptor zcytor17-multimerer
DE60323155D1 (de) Von transthyretin und zur hemmung von transthyretin-fehlfaltung
PL375021A1 (en) Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
DK15589D0 (da) Kemiske forbindelser
BR0007035A (pt) Métodos de controle de pragas de agrótis
ATE304858T1 (de) Mischung enthaltend einen inhibitor oder suppressor eines gens und ein molekül,dass an ein expressionprodukt dieses gens bindet
ITMI20021476A0 (it) Macchina vibrante particolarmente studiata per l'estrazione la miscelazione e la separazione di materie organiche ed inorganiche sia liquide
DK1674456T3 (da) Nye 1,4-benzothiazepin-1,1-dioxid-derivater med forbedrede egenskaber, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
EP1542721A4 (de) Modifizierte "s" antikörper
ID23053A (id) Karboksamida yang digunakan sebagai agonis 5-ht <if>
ITMI20020773A1 (it) Farmaci per il trattamento dell'artrite
DE60332579D1 (de) Prozess zur Immobilisierung von Polypeptiden über die Carboxylgruppe des C-terminus
DE50203845D1 (de) Schneckenförderer zum transport von an hängeträgern hängendem fördergut
ATE139570T1 (de) Expression signalpeptid-freier staphylokinasen
DE60021196D1 (de) Apoptose induzierende proteinesubstanz
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
ATE304995T1 (de) Stoffgemisch enthaltend bisphenol a
AT4620U3 (de) Gleisbaumaschine zur aufnahme von bettungsmaterial
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties